Can CYP2C19 help with Darmgesundheit?

CYP2C19 is a drug-metabolizing enzyme (Phase I) primarily known for processing medications like proton pump inhibitors (omeprazole) or antidepressants. A direct link to gut health is not scientifically established. Gut health is mainly determined by microbiome, diet, barrier function, and immunity – factors barely influenced by a single CYP variant. Some indirect effects are conceivable: CYP2C19 variants can alter omeprazole efficacy, potentially affecting stomach acid and gut flora long-term. However, robust human studies proving a clinically relevant benefit for gut health are lacking. Direct-to-consumer tests linking CYP2C19 to gut health are therefore marketing-driven. Evidence: mechanistic/insufficient. Caveat: No validated biomarkers for gut health from CYP2C19.